cabozantinib,pembrolizumab
exelixis,merck
['cabozantinib', 'pembrolizumab']
breaking data from #asco22: a potential treatment for patients with rmhnscc? phase ii study of pembrolizumab + cabozantinib met its primary endpoint of orr 45.2% with an overall clinical benefit of 90.4%! 